In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Genmab A/S stands fifth among them. Genmab A/S (NASDAQ:GMAB) is strengthening its position as a global leader in antibody-based therapies with both commercial successes and late-stage clinical progress in 2025. The company currently markets therapies such as Tivdak for cervical cancer and Epkinly for lymphoma, while advancing a robust pipeline targeting high-need oncology indications. A key milestone this y ...